Top Stories
Patients who received neoadjuvant Erleada were about 10 times more likely to have a major reduction of tumour cells by the time they got prostate surgery.
Results showed that the CDK4/6 inhibitor Verzenio (abemaciclib) was associated with progression-free survival of 9.7 months, a statistically significant improvement over 1.5 months seen for placebo.
Retevmo (selpercatinib) significantly improved event-free survival in patients with early-stage, RET fusion-positive non–small-cell lung cancer, reducing the risk of recurrence or death by about 83% over placebo.
RAS(ON) inhibitor daraxonrasib demonstrated OS and PFS efficacy across both RAS G12-mutant and overall populations in RASolute 302 study.
TUB-040 demonstrated a confirmed overall response rate of 61%, up from an earlier readout showing a cORR of 50%.
Conference News
100% ORR and MRD-negative responses observed in all evaluable patients, earliest dosed patients remain in ongoing MRD negative response beyond 9 monthsFavorable safety profile consistent with outpatie...
Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI...
Peer-Reviewed PublicationSociety of Nuclear Medicine and Molecular ImagingLos Angeles -- A new machine-learning approach for prostate-specific membrane antigen (PSMA) treatment of metastatic castratio...
Improved radiographic progression-free survival (rPFS) regardless of disease volume or metastatic presentation achieved with Pluvicto plus standard of care (ARPI + ADT) in PSMAdditionConsistent secon...
CHICAGO, May 31, 2026 (GLOBE NEWSWIRE) -- NeuExcell Therapeutics today announced that Dr. Yulun Huang will present the first-in-human clinical study of NXL-004 for recurrent malignant glioma as Rapid ...
